Xeljanz (Tofacitinib Citrate) Patent Expiration, LOE Window & CMS Spending
Xeljanz (Tofacitinib Citrate) by Pfizer: FDA Orange Book core substance LOE 2026-06-08 (last listed 2028-08-21), 12 AB generics, $404.2M 2024 CMS Part D & Medicaid spend, and 18 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pfizer |
| FDA Application & Pathway | N203214 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2026-06-08 |
| Last Listed Patent or Exclusivity Date | 2028-08-21 |
| Orange Book Patents (*PED Extensions) | 2 patents (1 *PED) |
| Active AB-Rated Generic Competitors | 12 |
| 2024 CMS Total Public Spend | $404.2M |
| 2024 Medicare Part D Spend | $273.8M |
| 2024 Medicaid Spend | $130.4M |
| Reported Wholesale Price Change (CA SB 17) | 18 WAC filings (max 17.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.